Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00395772 · ClinicalTrials.gov registry record · Phase 2
Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 543
- Enrollment target
NCT00395772: Completed Phase 2 study, sponsored by Bayer.
NCT00395772 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 543 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (308% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00395772, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 543 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the optimal dose of BAY 59-7939 and to compare the safety and effectiveness of this new drug with the standard way of treatment of deep vein thrombosis (heparin infusion plus one of the vitamin K antagonists), taking into account new events of thrombosis and pulmonary embolism and bleeding risk.
Interventions
- DRUG Xarelto (Rivaroxaban, BAY59-7939)
- DRUG (LMW) Heparin + Vitamin K Antagonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 543 participants |
| Start Date | 2004-12 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
What the finished NCT00395772 record still lists
NCT00395772 is an interventional study that assigns participants to a tested intervention. The registered 543 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (308% higher).
The record links to 0 conditions, and to 2 interventions - of which Xarelto (Rivaroxaban, BAY59-7939) is the first listed.
NCT00395772 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00395772 about?
NCT00395772 is a clinical study titled "Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis". The purpose of this study is to determine the optimal dose of BAY 59-7939 and to compare the safety and effectiveness of this new drug with the standard way of treatment of deep vein thrombosis (heparin infusion plus one of the vitamin K antagonists), taking into account new events of thrombosis and...
What is the current status of trial NCT00395772?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 543 participants. The study started on 2004-12. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00395772?
The interventions under investigation include: Xarelto (Rivaroxaban, BAY59-7939) (DRUG), (LMW) Heparin + Vitamin K Antagonist (DRUG).
Who is sponsoring clinical trial NCT00395772?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00395772's enrollment target sits among peer trials
543 62nd of 2000 higher than 1,939 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07294053 · 543 participants · NA
Sugary Drink Labeling Study
- NCT03127761 · 544 participants
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
- NCT04378790 · 544 participants · Phase 3
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
- NCT06118502 · 544 participants · NA
A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia